CTLA4 and glioma: The FDA-approved combination of nivolumab and ipilimumab for hepatocellular carcinoma has shown promising preclinical results in glioma models, where CTLA-4 and PD-1 blockade significantly extended survival, with 74% of mice achieving long-term responses (74, 75).